Terns Historical Financial Ratios
| TERN Stock | USD 5.71 0.11 1.96% |
Terns Pharmaceuticals is promptly reporting on over 92 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 3.14, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 6.52 will help investors to properly organize and evaluate Terns Pharmaceuticals financial condition quickly.
Terns |
About Terns Financial Ratios Analysis
Terns PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Terns Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Terns financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Terns Pharmaceuticals history.
Terns Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Terns Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Terns Pharmaceuticals sales, a figure that is much harder to manipulate than other Terns Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Effective Tax Rate
Effective Tax Rate is the average rate at which Terns Pharmaceuticals pre-tax profits are taxed by the government. The effective tax rate is computed by dividing Terns Pharmaceuticals total tax expenses by Terns Pharmaceuticals earnings before taxes.Most ratios from Terns Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Terns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.At this time, Terns Pharmaceuticals' Income Quality is very stable compared to the past year. As of the 22nd of November 2024, Ebt Per Ebit is likely to grow to 1.08, while PTB Ratio is likely to drop 1.72.
| 2021 | 2022 | 2023 | 2024 (projected) | PB Ratio | 1.11 | 1.32 | 1.81 | 1.72 | Capex To Depreciation | 0.66 | 0.27 | 0.059 | 0.0561 |
Terns Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Terns Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Terns Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 109.7 | 6.74 | 1.11 | 1.32 | 1.81 | 1.72 | |
| Book Value Per Share | 0.17 | 2.73 | 6.34 | 7.69 | 3.58 | 3.14 | |
| Operating Cash Flow Per Share | (2.64) | (1.19) | (1.66) | (1.36) | (0.95) | (0.99) | |
| Capex To Depreciation | 4.62 | 1.48 | 0.66 | 0.27 | 0.059 | 0.0561 | |
| Pb Ratio | 109.7 | 6.74 | 1.11 | 1.32 | 1.81 | 1.72 | |
| Free Cash Flow Per Share | (2.67) | (1.21) | (1.67) | (1.37) | (0.95) | (0.99) | |
| Roic | (16.68) | (0.46) | (0.31) | (0.22) | (0.4) | (0.42) | |
| Net Income Per Share | (2.74) | (1.61) | (1.98) | (1.67) | (1.27) | (1.33) | |
| Payables Turnover | 0.12 | 0.42 | 0.24 | 0.63 | 0.35 | 0.25 | |
| Cash Per Share | 0.78 | 2.98 | 6.57 | 7.86 | 3.7 | 3.4 | |
| Pocfratio | (6.97) | (15.5) | (4.27) | (7.47) | (6.86) | (7.21) | |
| Capex To Operating Cash Flow | (0.0136) | (0.0196) | (0.008129) | (0.0056) | (7.72E-4) | (8.1E-4) | |
| Pfcf Ratio | (6.88) | (15.2) | (4.24) | (7.43) | (6.86) | (7.2) | |
| Days Payables Outstanding | 3.1K | 866.18 | 1.5K | 581.81 | 1.0K | 989.87 | |
| Income Quality | 0.96 | 0.73 | 0.83 | 0.81 | 0.75 | 0.94 | |
| Roe | (16.36) | (0.59) | (0.31) | (0.22) | (0.35) | (0.37) | |
| Ev To Operating Cash Flow | (6.78) | (13.42) | (3.13) | (4.58) | (5.69) | (5.97) | |
| Pe Ratio | (6.71) | (11.39) | (3.56) | (6.08) | (5.13) | (5.38) | |
| Return On Tangible Assets | (2.88) | (0.44) | (0.3) | (0.21) | (0.34) | (0.35) | |
| Ev To Free Cash Flow | (6.69) | (13.16) | (3.11) | (4.55) | (5.68) | (5.97) | |
| Net Debt To E B I T D A | 0.35 | 1.69 | 0.97 | 2.41 | 0.78 | 0.74 | |
| Current Ratio | 4.49 | 3.98 | 24.48 | 33.68 | 22.39 | 16.83 | |
| Tangible Book Value Per Share | 0.17 | 2.73 | 6.34 | 7.69 | 3.58 | 3.14 | |
| Graham Number | 3.22 | 9.96 | 16.83 | 17.02 | 10.1 | 8.56 | |
| Shareholders Equity Per Share | 0.17 | 2.73 | 6.34 | 7.69 | 3.58 | 3.14 | |
| Capex Per Share | 0.0359 | 0.0232 | 0.0135 | 0.007632 | 7.3E-4 | 6.93E-4 | |
| Graham Net Net | (0.001873) | 2.47 | 6.26 | 7.58 | 3.51 | 3.03 | |
| Enterprise Value Over E B I T D A | (12.83) | (10.92) | (2.65) | (3.81) | (3.75) | (3.93) | |
| Price Earnings Ratio | (6.71) | (11.39) | (3.56) | (6.08) | (5.13) | (5.38) | |
| Price Book Value Ratio | 109.7 | 6.74 | 1.11 | 1.32 | 1.81 | 1.72 | |
| Days Of Payables Outstanding | 3.1K | 866.18 | 1.5K | 581.81 | 1.0K | 989.87 | |
| Price To Operating Cash Flows Ratio | (6.97) | (15.5) | (4.27) | (7.47) | (6.86) | (7.21) | |
| Price To Free Cash Flows Ratio | (6.88) | (15.2) | (4.24) | (7.43) | (6.86) | (7.2) | |
| Effective Tax Rate | 2.91E-4 | (0.0204) | (0.0102) | (0.005968) | (0.002656) | (0.002789) | |
| Return On Capital Employed | (3.7) | (0.53) | (0.31) | (0.22) | (0.4) | (0.42) |
Pair Trading with Terns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Terns Stock
Moving against Terns Stock
| 0.65 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.51 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.37 | KTTAW | Pasithea Therapeutics | PairCorr |
| 0.35 | VERA | Vera Therapeutics | PairCorr |
| 0.35 | DVAX | Dynavax Technologies | PairCorr |
The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 0.035 | Return On Assets (0.19) | Return On Equity (0.28) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.